Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease

Trial Profile

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

At a glance

  • Drugs Teprotumumab (Primary)
  • Indications Graves ophthalmopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIC
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 04 Sep 2018 According to a Horizon Pharma media release, top-line results from this study is expected in the second quarter of 2019.
    • 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.
    • 09 May 2018 According to a Horizon Pharma media release, the trial is 50 percent enrolled and is on track for enrollment completion by year end, or earlier.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top